Search results
Recce Pharmaceuticals doses first participants in next cohort Phase I/II UTI/Urosepsis rapid...
Proactive Investors· 5 hours agoRecce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has dosed the first participants in the next cohort...
Lumos Pharma plans phase 3 trial for growth hormone drug By Investing.com
Investing.com· 11 hours agoLumos Pharma Inc. (NASDAQ:LUMO), a biopharmaceutical company focused on rare diseases, announced...
Earnings call: Atea Pharmaceuticals reports progress in COVID-19 trial
Investing.com· 4 hours agoAtea Pharmaceuticals, a biopharmaceutical company focused on developing therapeutics for viral...
KORU Medical enters Phase III trial for rare disease therapy By Investing.com
Investing.com· 11 hours agoKORU Medical Systems, Inc. (NASDAQ: KRMD), a company specializing in large volume subcutaneous...
Earnings call: Ocugen reports progress in gene therapy trials and Q1 financials By Investing.com
Investing.com· 11 hours agoThe company highlighted the clearance of their Investigational New Drug (IND) application by the FDA...
Ocugen Inc (OCGN) Q1 2024 Earnings Call Transcript Highlights: S
Guru Focus· 2 hours agoFor the complete transcript of the earnings call, please refer to the full earnings call transcript. Ocugen Inc (OCGN, Financial) has received FDA clearance for its OCU400 Phase< ...
TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcri
Guru Focus· 36 minutes agoResearch and Development Expenses: $1.9 million for Q1 2024, down from $5 million in Q1 2023.General and Administrative Expenses: $1.4 million for Q1 2024, dec
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine...
WJTV Jackson· 20 hours agoAs part of the collaboration, PhaseV conducted an independent analysis of NeuroSense's PARADIGM Phase 2b study using a causal ML...
Kodiak Sciences dosing subjects in Phase III trial of diabetic retinopathy drug
Clinical Trials Arena via Yahoo Finance· 21 hours agoUS-based biotechnology company Kodiak Sciences has dosed the first subjects with diabetic...
Innovent’s mazdutide superior to Trulicity in Phase III T2D trial
Clinical Trials Arena via Yahoo Finance· 5 days agoThe US will maintain a majority of the global market share at 48.5%. GlobalData is the parent...